Submission of Letter of Offer regarding the open offer for acquisition of fully paid-up equity shares of Bliss GVS Pharma Limited from the Public Shareholders, by the Company together with PAC

ANUPAM RASAYAN INDIA LTD. ARILSLDSTX20260721034 Date: July 21, 2026 To, T o , BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, ‘Exchange Plaza’, C-1, Block-G, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai-400001, India Mumbai-400051, India SCRIP CODE: 543275 SYMBOL: ANURAS Dear Sir/Madam, Subject: Submission of a copy of the Letter of Offer sent to the Public Shareholders of Bliss GVS Pharma Limited (“Target Company”) regarding the Open Offer for acquisition of fully paid-up equity shares of face value of ₹ 1/- (Rupee One only) each, representing 26.00% (twenty six percent) of the Expanded Voting Share Capital of the Target Company from the Public Shareholders, by Anupam Rasayan India Limited (“Acquirer”) together with Mates Visa Consultancy Private Limited, in its capacity as person acting in concert (“PAC”) with the Acquirer for the purpose of the Open Offer, pursuant to and in compliance with the requirements of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Letter of Offer regarding the Open Offer for acquisition of fully paid-up equity shares of the Target Company from the Public Shareholders, by the Acquirer together with the PAC. This intimation will also be hosted on the Company’s website at www.anupamrasayan.com. We request you to kindly note the same and take into your records. Thanking you, Yours Faithfully, For Anupam Rasayan India Limited Ashish Gupta Company Secretary & Compliance Officer Encl.: As above Registered Office: Tel. : +91-261-2398991-95 Office Nos. 1101 to 1107, 11th Floor, Icon Rio, Fax : +91-261-2398996 Behind Icon Business Centre, Dumas Road, E-mail : office@anupamrasayan.com Surat-395007, Gujarat, India. Website : www.anupamrasayan.com CIN - L24231GJ2003PLC042988 LETTER OF OFFER THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION This Letter of Offer (as defined below) is being sent to you as a Public Shareholder (as defined below) of Bliss GVS Pharma Limited. If you require any clarification about the action to be taken, you may consult your stockbroker or investment consultant or the Manager to the Offer (as defined below)/ the Registrar to the Offer (as defined below). In case you have recently sold your Equity Shares (as defined below) in Bliss GVS Pharma Limited, please hand over this Letter of Offer and the accompanying Form of Acceptance-cum-Acknowledgement (as defined below) to the member of Stock Exchange (as defined below) through whom the said sale was effected. OPEN OFFER (“OPEN OFFER”/ “OFFER”) ANUPAM RASAYAN INDIA LIMITED A public limited company incorporated under the laws of India Regd. Office: Office Nos.1101 to1107, 11th Floor, Icon Rio, Behind Icon Business Centre, Dumas Road, Piplod, Surat, Gujarat - 395007 Corporate Identity Number (CIN): L24231GJ2003PLC042988 (Tel: 261-2398991-95; Fax: 261-2398996) (hereinafter referred to as the “Acquirer”) ALONGWITH MATES VISA CONSULTANCY PRIVATE LIMITED A private company incorporated under the laws of India Regd. Office: GN3-209, N.P.C. (New Prem Colony), Karnal, Karnal, Haryana, India, 132001 Corporate Identity Number (CIN): U74999HR2022PTC103913 (Tel: +91 9016564657) (hereinafter referred to as “PAC”) MAKES A CASH OFFER TO ACQUIRE UP TO 2,77,26,848 (TWO CRORE SEVENTY-SEVEN LAKH TWENTY-SIX THOUSAND EIGHT HUNDRED FORTY-EIGHT) FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹1 (INDIAN RUPEE ONE) EACH (“OFFER SHARES”) AT A PRICE OF ₹ 299.00 (INDIAN RUPEES TWO HUNDRED NINETY-NINE ONLY) PER EQUITY SHARE (“OFFER PRICE”), REPRESENTING 26.00% (TWENTY-SIX PER CENT.) OF THE EXPANDED VOTING SHARE CAPITAL (AS DEFINED BELOW) OF THE TARGET COMPANY (AS DEFINED BELOW), IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011 AND SUBSEQUENT AMENDMENTS THERETO (SEBI (SAST) REGULATIONS) FROM THE PUBLIC SHAREHOLDERS (AS DEFINED BELOW). BLISS GVS PHARMA LIMITED Regd. office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai, Maharashtra - 400072 Corporate identification Number: L24230MH1984PLC034771 (Tel: 022-42160000; Fax: 022-28563930 Email Address: Project.compliance@blissgvs.com; Website:www.blissgvs.com (hereinafter referred to as “Target Company”) 1. This Open Offer is being made by the Acquirer and the PAC, pursuant to and in compliance with the provisions of Regulation 3(1), Regulation 4 and other applicable regulations of the SEBI (SAST) Regulations. 2. This Open Offer is not a conditional offer in terms of Regulation 19 of the SEBI (SAST) Regulations and is not subject to any minimum level of acceptance. 3. This Open Offer is not a competing offer in terms of Regulation 20 of the SEBI (SAST) Regulations. 4. NRI (as defined below) and OCB (as defined below) holders of Equity Shares, if any, willing to tender their Equity Shares in this Open Offer, must obtain all requisite approvals required to tender the Equity Shares held by them in this Offer (including, without limitation, approval from the RBI (as defined below), or any other relevant statutory or regulatory authority, as may be applicable and submit copies of such approvals, along with the Form of Acceptance-cum-Acknowledgement and other documents required in terms of this Letter of Offer. Further, if holders of the Equity Shares who are not persons resident in India (including NRIs, OCBs, and FPIs (as defined below)), willing to tender their Equity Shares in this Open Offer, had required any approvals (including from the RBI or any other regulatory/statutory authority) in respect of the Equity Shares held by them at the time of original investment, they will be required to submit copies of such previous approvals, along with the other documents required to be tendered to accept this Open Offer. In the event such approvals are not submitted, the Acquirer and the PAC reserve the right to reject such Equity Shares tendered in this Open Offer. If the Equity Shares are held under general permission of the RBI, the non-resident Public Shareholder should state that the Equity Shares are held under general permission and clarify whether the Equity Shares are held on a repatriable or a non-repatriable basis. 5. There are no statutory or regulatory approvals required by the Acquirer and/ or the PAC, to acquire the Equity Shares validly tendered by Public Shareholders pursuant to this Open Offer. However, in case of any other statutory or regulatory approvals being required and/or becoming applicable at a later date, before the closing of the Tendering Period (as defined below), this Open Offer would be subject to the receipt of such approvals. Please refer to Part C (Statutory and Other Approvals) of Section VIII (Terms and Conditions of the Open Offer) of this Letter of Offer for further details and the current status of such statutory and governmental approval(s). 6. Where any statutory or other approval extends to some but not all of the Public Shareholders, the Acquirer and PAC shall have the option to make payment to such Public Shareholders in respect of whom no statutory or other approvals are required in order to complete this Open Offer. 7. The Acquirer and the PAC may withdraw the Open Offer in accordance with the terms and conditions specified in Part C (Statutory and Other Approvals) of Section VIII (Terms and Conditions of the Open Offer) of this Letter of Offer. In the event of a withdrawal of the Open Offer, the Acquirer and the PAC (through the Manager) shall, within 2 (two) Working Days (as defined below) of such withdrawal, make a public announcement, in the same Newspapers (as defined below) in which the Detailed Public Statement (as defined below) was published, in accordance with Regulation 23(2) of the SEBI (SAST) R [Showing first 8,000 characters — download PDF for full document]